Dr. Tara Kieffer, PhD, is Director of Clinical Biomarkers at Vertex Pharmaceuticals Incorporated in Cambridge MA, USA. Dr. Kieffer has worked at Vertex since October of 2004, performing laboratory research studies to understand the development of antiviral drug resistance to direct-acting antivirals (DAAs) for HCV.
Her group focuses on generating, analyzing, and interpreting HCV sequence data from clinical trials and phenotypic characterization of HCV variants to understand in vivo HCV resistance to DAAs and optimize treatment regimens.
Dr. Kieffer received her PhD degree in 2004 from Johns Hopkins University School of Medicine, in Baltimore MD, USA, in the Department of Molecular Biology and Genetics, Graduate Program in Immunology. She worked in the laboratory of Robert Siliciano, where her research studies focused on ongoing replication in well suppressed HIV patients on HAART. In 1999, Dr. Kieffer received her Bachelor of Arts degree summa cum laude with High Honors in the field of molecular biology from Colgate University in Hamilton NY, USA.